Synthesis of polymyxin analogs with enhanced activity towards Gram-negative biofilm-associated infections

dc.commentsCEB58476
dc.contributor.authorGrainha, Tânia
dc.contributor.authorMartins, Elsa
dc.contributor.authorCosta, Susana Paula
dc.contributor.authorJorge, Paula
dc.contributor.authorLopes, Susana Patrícia
dc.date.accessioned2025-11-25T11:51:11Z
dc.date.issued2024-05-17
dc.date.updated2025-09-07T12:24:00Z
dc.description.abstract[Excerpt] Polymyxins (PM) B and E are last-resort drugs against Gram-negative bacterial infections (often biofilm-related), but resistance and toxicity compromise PM use. A fast-growing no. of PM analogs have been reported, but with varied success in improving PM activity and ameliorating toxicity. ,-Dialkylglycines (DAG), unnatural amino acids, hold unique characteristics (bioactivity, metabolic resistance, hydrophobicity, stability), being innovative building blocks in PM analog design. We report 6 new PM analogs synthesis and activity against planktonic and biofilm cultures, including PM analog combination with common antibiotics. Two DAGs, diisobutyl glycine (Dibg) and dibenzyl glycine (Dbng), were synthesised by Ugi multicomponent reaction and assembled in situ at positions 6 and/or 7 of native PMB/E through microwave assisted solid-phase peptide synthesis. Antibacterial/antibiofilm activities were assessed against 24-h old Pseudomonas aeruginosa ATCC 27853 cultures (broth microdilution; culturable biofilm cells), including synergy evaluation with ciprofloxacin (CIP) and tobramycin (TOB) (checkerboard assays; anti-biofilm activity). The 2 analogs with Dibg at position 7 (PMBa/PMEa) were the most promising, with PMBa having MIC/MBC of 4 mg/L and no cytotoxicity towards A549 lung epithelial cells. Preliminary HPLC analysis indicates ~66% purity, meaning that pure analog concentrations are ~2 mg/L, close to that of PMB (1 mg/L). Furthermore, 512 mg/L (~340 mg/L pure analog) of PMBa decreased biofilm cell numbers by 3.7 log(CFU/mL), which is promising considering that PMB achieved a similar reduction, ~3.9 log(CFU/mL), for a higher effective concentration (512 mg/L). In turn, PMBb/PMEb (Dbng at position 6) and PMBc (Dbng at position 6 + Dibg at position 7) analogs were the most promising in combination scenarios, achieving synergic/additive outcomes (FICI between 0.3125 and 0.75) when combined with TOB/CIP against planktonic cells. Preliminary results still show potential synergy of PMEb+TOB with decreased biofilm cell numbers ~3.4 log(CFU/mL). [...]eng
dc.description.sponsorshipWe acknowledge the FCT-funded project POLYmix-POLYmic (DOI:10.54499/2022.06595.PTDC), the programmatic funding to CQUM (DOI:10.54499/UIDB/00686/2020) and CEB (DOI:10.54499/UIDB/04469/2020), and the contracts of the author PJ (DOI:10.54499/2020.00194.CEECIND/CP1600/CT0021) and SL (DOI:10.54499/DL57/2016/CP1377/CT0043).
dc.distributionnational
dc.identifier.citationGrainha, Tânia; Martins, Elsa; Costa, Susana Paula; Jorge, Paula; Lopes, Susana P., Synthesis of polymyxin analogs with enhanced activity towards Gram-negative biofilm-associated infections. 6EBTM - 6th Meeting of Medicinal Biotechnology. Porto, Portugal, May 17, 14, 2024.
dc.identifier.urihttps://hdl.handle.net/1822/98294
dc.language.isoeng
dc.peerreviewedyes
dc.relation2022.06595.PTDC
dc.relationUIDB/00686/2020
dc.relationUIDB/04469/2020
dc.rightsopenAccess
dc.rights.uriN/A
dc.subjectPolymyxin analogs
dc.subjecta,a-Dialkylglycines
dc.subjectanti-biofilm
dc.subjectcombination therapy
dc.titleSynthesis of polymyxin analogs with enhanced activity towards Gram-negative biofilm-associated infectionseng
dc.typeconferenceAbstract
dspace.entity.typePublicationen
oaire.citationConferencePlacePorto, Portugal
oaire.citationStartPage14
oaire.versionhttp://purl.org/coar/version/c_ab4af688f83e57aa
sdum.conferencePublication6EBTM - 6th Meeting of Medicinal Biotechnology

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_58476_1.pdf
Tamanho:
77.85 KB
Formato:
Adobe Portable Document Format